Antonis S. Zervos
Harvard University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Antonis S. Zervos.
Cell | 1993
Antonis S. Zervos; Jenő Gyuris; Roger Brent
Abstract We used the interaction trap to isolate a novel human protein that specifically interacts with Max. This protein, Mxi1 (for Max interactor 1), contains a bHLH-Zip motif that is simillar to that found in Myc family proteins. Mxi1 interacts specifically with Max to form heterodimers that efficiently bind to the Myc-Max consensus recognition site. When bound to DNA by a LexA moiety in yeast, Mxi1 does not stimulate transcription. mxi1 mRNA is expressed in many tissues, and its expression is elevated in U-937 myeloid leukemia cells that have been stimulated to differentiate. These facts are consistent with a model in which Mxi1-Max heterodimers indirectly inhibit Myc function in two ways: first, by sequestering Max, thus preventing the formation of Myc-Max heterodimers, and second, by competing with Myc-Max heterodimers for binding to target sites.
Journal of Biological Chemistry | 2000
Lucia Faccio; Carlo Fusco; Ang Chen; Stefano Martinotti; Joseph V. Bonventre; Antonis S. Zervos
We report the isolation and characterization of a cDNA encoding the novel mammalian serine protease Omi. Omi protein consists of 458 amino acids and has homology to bacterial HtrA endoprotease, which acts as a chaperone at low temperatures and as a proteolytic enzyme that removes denatured or damaged substrates at elevated temperatures. The carboxyl terminus of Omi has extensive homology to a mammalian protein called L56 (human HtrA), but unlike L56, which is secreted, Omi is localized in the endoplasmic reticulum. Omi has several novel putative protein-protein interaction motifs, as well as a PDZ domain and a Src homology 3-binding domain. Omi mRNA is expressed ubiquitously, and the gene is localized on human chromosome 2p12. Omi interacts with Mxi2, an alternatively spliced form of the p38 stress-activated kinase. Omi protein, when made in a heterologous system, shows proteolytic activity against a nonspecific substrate β-casein. The proteolytic activity of Omi is markedly up-regulated in the mouse kidney following ischemia/reperfusion.
Journal of Biological Chemistry | 2004
Lucia Cilenti; Mangala M. Soundarapandian; George A. Kyriazis; Valerie Stratico; Supriya Singh; Sanjeev Gupta; Joseph V. Bonventre; Emad S. Alnemri; Antonis S. Zervos
Omi/HtrA2 is a nuclear-encoded mitochondrial serine protease that has a pro-apoptotic function in mammalian cells. Upon induction of apoptosis, Omi translocates to the cytoplasm and participates in caspase-dependent apoptosis by binding and degrading inhibitor of apoptosis proteins. Omi can also initiate caspase-independent apoptosis in a process that relies entirely on its ability to function as an active protease. To investigate the mechanism of Omi-induced apoptosis, we set out to isolate novel substrates that are cleaved by this protease. We identified HS1-associated protein X-1 (HAX-1), a mitochondrial anti-apoptotic protein, as a specific Omi interactor that is cleaved by Omi both in vitro and in vivo. HAX-1 degradation follows Omi activation in cells treated with various apoptotic stimuli. Using a specific inhibitor of Omi, HAX-1 degradation is prevented and cell death is reduced. Cleavage of HAX-1 was not observed in a cell line derived from motor neuron degeneration 2 mice that carry a mutated form of Omi that affects its proteolytic activity. Degradation of HAX-1 is an early event in the apoptotic process and occurs while Omi is still confined in the mitochondria. Our results suggest that Omi has a unique pro-apoptotic function in mitochondria that involves removal of the HAX-1 anti-apoptotic protein. This function is distinct from its ability to activate caspase-dependent apoptosis in the cytoplasm by degrading inhibitor of apoptosis proteins.
Journal of Biological Chemistry | 2003
Lucia Cilenti; Younghee Lee; Sibylle Hess; Srinivasa M. Srinivasula; Kwon Moo Park; Daniela Junqueira; Hedvika Davis; Joseph V. Bonventre; Emad S. Alnemri; Antonis S. Zervos
Omi/HtrA2 is a mammalian serine protease with high homology to bacterial HtrA chaperones. Omi/HtrA2 is localized in mitochondria and is released to the cytoplasm in response to apoptotic stimuli. Omi/HtrA2 induces cell death in a caspase-dependent manner by interacting with the inhibitor of apoptosis protein as well as in a caspase-independent manner that relies on its protease activity. We describe the identification and characterization of a novel compound as a specific inhibitor of the proteolytic activity of Omi/HtrA2. This compound (ucf-101) was isolated in a high throughput screening of a combinatorial library using bacterially made Omi-(134–458) protease and fluorescein-casein as a generic substrate. ucf-101 showed specific activity against Omi/HtrA2 and very little activity against various other serine proteases. This compound has a natural fluorescence that was used to monitor its ability to enter mammalian cells. ucf-101, when tested in caspase-9 (−/−) null fibroblasts, was found to inhibit Omi/HtrA2-induced cell death.
Yeast | 1999
Carlo Fusco; Elena Guidotti; Antonis S. Zervos
We describe a simple and efficient one‐step method to make cDNA libraries using homologous recombination in yeast. cDNA from any source, together with a linear vector, is used to transform yeast. Through homologous recombination and gap repair, the cDNA is unidirectionally incorporated into the yeast expression vector in vivo. The cDNA‐encoded proteins can then be screened for potential protein–protein interactions with a bait already present in the yeast. This method allows rapid construction and screening of cDNA libraries, even from extremely small amounts of mRNA, and can replace the use of conventional cDNA libraries. Copyright
Journal of Biological Chemistry | 2002
Ramesh Hegde; Srinivasa M. Srinivasula; ZhiJia Zhang; Richard Wassell; Rula Mukattash; Lucia Cilenti; Garrett DuBois; Yuri Lazebnik; Antonis S. Zervos; Teresa Fernandes-Alnemri; Emad S. Alnemri
Oncogene | 1994
Susanne Edelhoff; Donald E. Ayer; Antonis S. Zervos; Eiríkur Steingrímsson; Nancy A. Jenkins; Neal G. Copeland; Robert N. Eisenman; Roger Brent; Christine M. Disteche
Genomics | 1998
Carlo Fusco; Alexandre Reymond; Antonis S. Zervos
Archive | 1993
Roger Brent; Antonis S. Zervos
Genomics | 2000
Lucia Faccio; Carlo Fusco; Alain Viel; Antonis S. Zervos